Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.
ViaCyte
Life Sciences, Venture Debt
Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.